The estimated Net Worth of Earl M Jr Collier is at least $238 Tysiąc dollars as of 23 April 2024. Mr. Collier owns over 30,000 units of Capricor Therapeutics Inc stock worth over $237,658 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $0 as Independent Director at Capricor Therapeutics Inc.
Sign up
Mr. Collier CAPR stock SEC Form 4 insiders trading
Earl has made over 4 trades of the Capricor Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of CAPR stock worth $41,700 on 23 April 2024.
The largest trade he's ever made was exercising 30,000 units of Capricor Therapeutics Inc stock on 23 April 2024 worth over $41,700. On average, Earl trades about 2,843 units every 39 days since 2015. As of 23 April 2024 he still owns at least 56,856 units of Capricor Therapeutics Inc stock.
You can see the complete history of Mr. Collier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Earl Collier biography
Earl M. Collier (Duke), Jr. Esq. is Independent Director of CAPRICOR THERAPEUTICS,. He joined the Capricor Board of Directors in 2011 and is a member of the Nominating and Corporate Governance Committee. He is currently the chief executive officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and serves as a Senior Advisor to Polaris Venture Partners, a venture capital firm focused on information technology and life sciences, and as executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and overseeing the company’s efforts in multiple sclerosis and other immune disorders. He has also led some of Genzyme’s significant acquisitions and the formation of MG Biotherapeutics, Genzyme’s joint venture with Medtronic Inc., which is focused on cardiac cell therapy. Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the U.S. Department of Health & Human Services. Mr. Collier sits on the boards of several corporations including Arsenal Medical, Inc. and Pervasis Therapeutics, a biotechnology company. He is also chairman of the board for the Newton-Wellesley Hospital. From 2006 to 2009, Mr. Collier served as a director of publicly traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School.
How old is Earl Collier?
Earl Collier is 70, he's been the Independent Director of Capricor Therapeutics Inc since 2013. There are 2 older and 15 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
What's Earl Collier's mailing address?
Earl's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Insiders trading at Capricor Therapeutics Inc
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... oraz Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
What does Capricor Therapeutics Inc do?
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
What does Capricor Therapeutics Inc's logo look like?
Complete history of Mr. Collier stock trades at Capricor Therapeutics Inc
Capricor Therapeutics Inc executives and stock owners
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Karen G. Krasney,
Exec. VP, Gen. Counsel & Sec. -
Anthony J. Bergmann M.B.A.,
CFO & Corp. Treasurer -
Karen Krasney,
Executive Vice President, General Counsel -
Linda Marban,
President, Chief Executive Officer, Director -
Dr. Linda Marbán,
Co-Founder, Pres, CEO & Director -
Dr. Frank Isaac Litvack FACC, M.D.,
Exec. Chairman -
Dr. Frank Isaac Litvack M.D., FACC,
Exec. Chairman -
Joshua Kazam,
Director -
David Musket,
Independent Director -
Louis Manzo,
Independent Director -
Louis Grasmick,
Independent Director -
George Dunbar,
Independent Director -
Earl Collier,
Independent Director -
Deborah Ascheim,
Chief Medical Officer -
Rachel Smith,
Vice President - Research & Development -
Luis Rodriguez-Borlado,
Vice President - Regenerative Therapies -
Houman Hemmati,
Vice President - Medical & Clinical Development, New Therapies -
Thomas Copmann,
Vice President - Regulatory Affairs and Drug Development -
Anthony Bergmann,
Chief Financial Officer, Principal Accounting Officer -
Frank Litvack,
Independent Executive Chairman of the Board -
Catherine Lee Kelleher,
Consultant -
Dr. Deborah D. Ascheim,
Consultant -
Dr. Eduardo Marbán,
Co-Founder & Chairman of Scientific Advisory Board -
Leland Gershell,
CHIEF FINANCIAL OFFICER -
John Edward A.Edward St. Jo...,
-
Sinai Medical Center Cedars,
10% owner -
Xavier Avat,
-
Philip J Gotwals,
-
Paul Gisbert Auwaerter,
-
Eduardo Marban,
10% owner -
Gregory W Schafer,
Director -
Mike Kelliher,
-
Karimah Es Sabar,